Pulnovo Medical Showcases PADN Clinical Program at CRT 2026

A LinkedIn post from Pulnovo Medical highlights plans to feature its Pulmonary Artery Denervation, or PADN, clinical trials at the CRT 2026 conference in Washington, D.C. The post points to two late-breaking presentations focused on pulmonary hypertension and heart failure indications.

According to the post, presentations by Dr. Gregg W. Stone and Dr. Giora Weisz will discuss PADN in combined pre- and post-capillary pulmonary hypertension in heart failure, as well as pulmonary hypertension secondary to left heart disease. This emphasis on late-breaking data suggests Pulnovo is moving its PADN platform further along the clinical validation pathway, which could be significant for future regulatory and commercialization prospects in the MedTech cardiopulmonary niche.

For investors, the focus on pulmonary hypertension and heart failure signals continued targeting of large, high-burden cardiovascular markets where unmet need remains substantial. While the post does not provide specific trial results, the visibility at a specialized interventional cardiology meeting may enhance Pulnovo’s scientific profile, support potential partnering discussions, and, if data prove positive, eventually underpin valuation expectations around the PULSE LHD program and related PADN assets.